Characteristics and biological behaviour of 99mTc-labelled hydroxyacetyltriglycine, a potential alternative to 99mTc-MAG3

European Journal of Nuclear Medicine

Volumn 24, Issue 11, 1997, Pages 1374-1379

  Vanbilloen, Hubert P ^a   Dezutter, Nancy A ^b   Cleynhens, Bernard J ^a   Verbruggen, Alfons M ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Biodistribution studies; Biological behaviour; Hydroxyacetyltriglycine; Labelling characteristics; Mercaptoacetyltriglycine

Indexed keywords

HYDROXYACETYLTRIGLYCINE TC 99M; MERTIATIDE TC 99M; UNCLASSIFIED DRUG;

ALKALINITY; ARTICLE; ELECTROPHORESIS; MOUSE; NONHUMAN; PLASMA CLEARANCE; PLASMA PROTEIN BINDING; RADIODIAGNOSIS; URINARY EXCRETION;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, PAPER; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; ISOTOPE LABELING; MALE; MICE; PAPIO; PROTEIN BINDING; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M MERTIATIDE; TISSUE DISTRIBUTION;

EID: 0030714158     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050163     Document Type: Article

References (20)

1. Troutner DE, Simon J, Ketring AR, Volkert WA, Holmes RA. Complexing of Tc-99m with cyclam: concise communication. J Nucl Med 1980; 21: 443-448.
2. Vanbilloen HP, Bormans GM, De Roo MJ, Verbruggen AM. Complexes of technetium-99m with tetrapeptides containing one alanyl and three glycyl moieties. Eur J Nucl Med 1996; 23: 40-48.
3. 99mTc-labelled agents. Nucl Med Biol 1995; 22: 325-338.
4. 99mTc-labeled radiopharmaceuticals for renal imaging. J Nucl Med 1971; 12: 399.
5. 99mTc-complexes. J Nucl Med 1975; 16: 357-367.
6. 99mTc-Zinn-Komplexes für die Nierenzintigraphie. Nucl Med 1969; 8: 301-305.
7. 99mTc-gluconate complexes for renal scintigraphy. Br J Radiol 1973; 46: 604-612.
8. de Kievit W. Technetium radiopharmaceuticals: chemical characterization and tissue distribution of Tc-glucoheptonate using Tc-99m and carrier Tc-99. J Nucl Med 1981; 22: 703-709.
9. 99mTc-chelate substitute for organoradiomercurial renal agents. J Nucl Med 1974; 15: 34-35.
10. 99mTc-dimercaptosuccinic acid. Clin Nucl Med 1979; 4: 39-47.
11. Taylor A Jr. Quantitation of renal function with static imaging agents. Semin Nucl Med 1982; 12: 330-344.
12. Kipper MS, Witzum KF, Taylor A Jr. Visual determination of differential renal function. Clin Nucl Med 1986; 11: 313-318.
13. Moretti JL, Rapin JR, Saccavini JC, Lageron A, Le Poncin M, Bardy A. 2,3-dimercaptosuccinic acid chelates: their structure and biological behaviour. In: Raynaud C, ed. Nuclear medicine and biology. Proceedings of the third world congress of nuclear medicine and biology. New York: Pergamon Press; 1982: 1651-1654.
14. m (V) DMSA. Nucl Med Commun 1987; 8: 184-185.
15. 99mTc]MDP - an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 1988; 29: 33-38.
16. Watkinson JC, Lazarus CR, Mistry R, Shaheen OH, Maisey MN, Clarke SE. Technetium-99m (V) dimercaptosuccinic acid uptake in patients with head and neck squamous carcinoma: experience in imaging. J Nucl Med 1989; 30: 174-180.
17. 3 and biodistribution of by-products. J Appl Radiat Isot 1988; 39: 121-129.
18. Ringshaw DJ, Smith. Alkaline hydrolysis of O-acylglycolic esters. Part I. J Am Chem Soc 1964; 86: 1559-1562.
19. Verbruggen AM, Nosco DL, Van Nerom CG, Bormans GM, Adriaens PJ, De Roo MJ. Technetium-99m-L,L-ethylenedicysteine: a renal imaging agent. I. Labelling and evaluation in animals. J Nucl Med 1992; 33: 551-557.
20. Sapirstein LA, Vidt DG, Mandel MJ, Hanusek G. Volume of distribution and clearance of intravenously injected creatinine in the dog. Am J Physiol 1955; 181: 330-336.